NewAmsterdam Pharma (NasdaqGM:NAMS) has wrapped up FY 2025 with fourth quarter revenue of about US$0.03 million and a quarterly loss of US$74.9 million, equal to a basic EPS loss of US$0.62. This puts a spotlight on how much cash is still going into development. The company has seen quarterly revenue range from US$0.03 million to US$19.1 million over the past four quarters, while EPS moved between a loss of US$0.15 and a loss of US$0.93, keeping margins firmly in loss making territory even as growth expectations remain focused on future revenue expansion.

See our full analysis for NewAmsterdam Pharma.

Next up is how these numbers line up against the main market narratives around growth potential, risk, and valuation, and where those stories hold up or get pushed back by the latest results.

US$203.8 million loss over the year

• Over the last twelve months, NewAmsterdam Pharma recorded a net loss of US$203.8 million on total revenue of US$22.5 million, which means expenses have outweighed revenue by a wide margin across FY 2025.
• Bears often focus on this scale of loss, and the data supports that concern, but it also shows where the debate sits:
  • Losses have grown at about 43.3% per year over the past five years, which aligns with the bearish view that spending has ramped up faster than the current revenue base.
  • At the same time, revenue is forecast to grow at 51.3% per year, so the key bearish question is whether this pace of top line growth can eventually catch up with consistently high expenses.

Forecast 51.3% revenue growth vs ongoing losses

• Revenue is forecast to grow about 51.3% per year, while the company is expected to remain loss making for at least the next three years, so the growth story currently sits alongside continued red ink.
• Supporters of a more bullish angle point to this strong growth forecast, and the numbers help explain why they pay close attention to it:
  • Trailing twelve month revenue of US$22.5 million compares with quarterly revenue that has swung between US$0.03 million and US$19.1 million, highlighting how early revenue is but also how quickly it can ramp when milestones or agreements come through.
  • Because net income over the same trailing period sits at a loss of US$203.8 million, the bullish case rests on the idea that future revenue growth of around 51.3% per year can at some point support the current spending needed to develop the pipeline.

Bulls and skeptics are reading the same growth and loss figures very differently right now, so it helps to see how other investors are joining the dots between revenue, losses, and valuation in one place. Curious how numbers become stories that shape markets? Explore Community Narratives

DCF fair value far above share price

• The current share price of US$34.85 sits well below both the DCF fair value estimate of about US$137.55 and the analyst price target of roughly US$49.49, while the P/B ratio of 5.9x is slightly above peers at 5.7x and well above the US Biotechs industry average of 2.5x.
• What stands out for the bullish valuation narrative is how mixed these signals are when placed side by side:
  • On one hand, trading about 74.7% below the DCF fair value and around 42% below the analyst price target is the core of the upside argument that the market is pricing the stock well under the cash flow and target based estimates.
  • On the other hand, a P/B of 5.9x above both peers and the wider industry, alongside recent insider selling over the past three months, gives bears specific balance sheet and behaviour based reference points when they question how much of that theoretical upside is already reflected in expectations.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on NewAmsterdam Pharma's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With such mixed signals on growth, losses, and valuation, it is worth checking the underlying data yourself and deciding where you land on the story. To move from headline impressions to your own judgment, start by weighing the company specific risks and potential rewards through the 3 key rewards and 2 important warning signs.

Explore Alternatives

NewAmsterdam Pharma is carrying sizeable losses of US$203.8 million on US$22.5 million in revenue, with ongoing red ink and mixed valuation signals.

If you want ideas with less focus on heavy losses and more on financial resilience, check out the 72 resilient stocks with low risk scores today to compare alternatives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.